BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...

Bayer revealed first results of the pediatric study from the pivotal clinical development program QUANTI for its low-dose MRI contrast agent QUANTI Pediatric evaluated the pharmacokinetics and safety ...

Bayer AG (OTCMKTS:BAYRY) is among the best German stocks to buy according to analysts. On March 5, Bayer AG (OTCMKTS:BAYRY) announced that the FDA has cleared its MEDRAD MRXperion MR injector system ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/x2jzvc/eu5_contrast) has announced the addition of the "EU5 Contrast Media ...

Bayer submitted an application to the U.S.'s Food and Drug Administration to get approval for its gadoquatrane agent, a substance used to improve the quality of magnetic resonance imaging scans. The ...

Bayer HealthCare Pharmaceuticals, a Wayne, N.J., provider of diagnostic imaging technology, has launched VistaTrak, an RFID-based system designed to help hospitals monitor the use of contrast media—an ...

DUBLIN, Nov. 11, 2019 /PRNewswire/ -- The "North America Contrast Media Injectors Market to 2025 - Regional Analysis and Forecasts by Product; Application; and Country" report has been added to ...

The global market for contrast media injectors is poised for significant growth, projected to reach $2.1 billion by 2033 at a CAGR of 7.8% between 2025 and 2033. This expansion is fueled by ongoing ...

Bayer BAYRY announced that it has submitted a new drug application (“NDA”) to the FDA seeking approval for its investigational low-dose gadolinium-based contrast agent (“GBCA”), gadoquatrane, for use ...